Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind (Observer-blind), Randomised, Controlled, Phase I/II Study, to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months to Healthy PPD-positive Volunteers Aged 18 to 50 Years

NCT00146744 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00146744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00146744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind (Observer-blind), Randomised, Controlled, Phase I/II Study, to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months to Healthy PPD-positive Volunteers Aged 18 to 50 Years
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
May 31, 2006
Enrollment
38
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis (tb)